Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy (2006)
Gotlib, Jason, Cross, N.C.P., Gilliland, D. Gary
Before the 1990s, lack of evidence for a reactive cause of hypereosinophilia or chronic eosinophilic leukemia (e.g. presence of a clonal cytogenetic abnormality or increased blood or bone marrow...
Curtis, Claire, Apperley, Jane F., Dang, Raymond, Jeng, Michael, Gotlib, Jason, Cross, Nicholas C.P., ...
We have identified three patients (2 adults, one infant) who presented with BCR-ABL negative eosinophilic myeloproliferative disorders. Cytogenetic analysis revealed a t(1;3;5)(p36;p21;q33) for case...
Stover, Elizabeth H, Boulton, Christina L, Gotlib, Jason, Legare, Robert D, Amaral, Sonia M, ...
FIP1L1-PDGFRalpha causes hypereosinophilic syndrome (HES) and is inhibited by the tyrosine kinase inhibitor imatinib (Gleevec). Imatinib is a potent inhibitor of ABL, ARG, PDGFRalpha, PDGFRbeta, and...
Cools, Jan, DeAngelo, Daniel J., Gotlib, Jason, Stover, Elizabeth H., Legare, Robert D., Cortes, Jorges, ...
BACKGROUND: Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia associated with organ dysfunction. It is of unknown cause. Recent reports of responses to imatinib in...
DeAngelo, Daniel J, Gotlib, Jason, Stover, Elizabeth H, Legare, Robert D, Cortes, Jorges, ...
BACKGROUND: Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia associated with organ dysfunction. It is of unknown cause. Recent reports of responses to imatinib in...
Cools, Jan, DeAngelo, Daniel J., Gotlib, Jason, Stover, Elizabeth. H., Legare, Robert. D., Cortes, Jorges, ...
BACKGROUND: Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia associated with organ dysfunction. It is of unknown cause. Recent reports of responses to imatinib in...
Jamieson, Catriona H. M., Gotlib, Jason, Durocher, Jeffrey A., Chao, Mark P., Mariappan, M. Rajan, Lay, Marla, ...
Although a large proportion of patients with polycythemia vera (PV) harbor a valine-to-phenylalanine mutation at amino acid 617 (V617F) in the JAK2 signaling molecule, the stage of hematopoiesis at...
Jamieson, Catriona H. M., Gotlib, Jason, Durocher, Jeffrey A., Chao, Mark P., Mariappan, M. Rajan, Lay, Marla, ...
Although a large proportion of patients with polycythemia vera (PV) harbor a valine-to-phenylalanine mutation at amino acid 617 (V617F) in the JAK2 signaling molecule, the stage of hematopoiesis at...
Gotlib, Jason, Berubé, Caroline, Growney, Joseph D., Chen, Ching-Cheng, George, Tracy I., Williams, Christopher, ...
The majority of patients with systemic mast cell disease express the imatinib-resistant Asp816Val (D816V) mutation in the KIT receptor tyrosine kinase. Limited treatment options exist for aggressive...
Detection of the JAK2 V617F Mutation by LightCycler PCR and Probe Dissociation Analysis
Lay, Marla, Mariappan, Rajan, Gotlib, Jason, Dietz, Lisa, Sebastian, Siby, Schrijver, Iris, ...
A point mutation in the JAK2 gene, a member of the tyrosine kinase family, was recently identified and shown to be associated with several myeloproliferative disorders. Several studies identified the...
Lancet, Jeffrey E., Gojo, Ivana, Gotlib, Jason, Feldman, Eric J., Greer, Jacqueline, Liesveld, Jane L., ...
Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors. In this phase 2 study, we tested the oral farnesyltransferase inhibitor...
Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation
Abrahamsson, Annelie E., Geron, Ifat, Gotlib, Jason, Dao, Kim-Hien T., Barroga, Charlene F., Newton, Isabel G., ...
Recent evidence suggests that a rare population of self-renewing cancer stem cells (CSC) is responsible for cancer progression and therapeutic resistance. Chronic myeloid leukemia (CML) represents an...